10 results about "Chronic traumatic encephalopathy" patented technology

Diagnostic and therapeutic methods for neurodegenerative diseases. Are provided involving assaying abnormal proteins (hyperphosphorylated tau, α-synuclein, TDP-43) associated with neuronal turnover inhibition or promotion in patient samples. Abnormal protein expression and apoptotic activity are detected, aiding disease progression assessment. Therapeutically, a method is provided for treating neurodegenerative diseases, administering compounds promoting neuronal turnover or modulating proteins involved in the process. The invention extends to identifying suitable drugs, employing neuronal turnover induction, miRNA modulation, and protein activity inhibition or enhancement. The claims also encompass various species, tissues, and cultured cells. Furthermore, the invention is applicable to diverse neurodegenerative diseases with abnormal protein accumulation, presenting novel diagnostic and treatment approaches.

The invention is directed to immunological compositions of one or more peptides containing epitopes of PGN, LTA and LPS molecules that induce an immunological response in a mammal, and to multiple antibodies that bind to these epitopes. Immunological compositions and antibodies disclosed herein can be used in the treatment and / or prevention of human health disorders such as bacterial sepsis, inflammation, cancers, tumors, inflammatory diseases and disorders, and neurodegenerative disorders such as, but not limited to Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia and / or limbic predominant age-related TDP-43 encephalopathy (LATE).

Disclosed are compounds of Formulas (I), (la), (lb), (II), (Ila), (III), (Illa), and (Illb), as well as pharmaceutical compositions thereof. The compounds can be used to improve proteostasis and enhance clearance of protein accumulation events by positively modulating the autophagy-lysosomal pathway, including augmenting the activity of cathepsin enzymes, and / or to treat neurological diseases, disorders and conditions, such as, but not limited to, Alzheimer's disease, Parkinson's disease, Huntington's disease, mild cognitive impairment, frontotemporal dementia, amyotrophic lateral sclerosis, Lewy body dementias, chronic traumatic encephalopathy, traumatic brain injury, and α-synucleinopathies.

Provided herein are compositions and methods for treating neuroinflammatory diseases and conditions, the neuroinflammatory diseases and conditions include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), optic neuromyelitis (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), vascular dementia (VAD), anti-oligodendroglia glycoprotein antibody disease (MOGAD), and the like. Transverse myelitis (TM), autoimmune encephalitis (AE), acute disseminated encephalomyelitis (ADEM), chronic meningitis (CM), central nervous system (CNS) vasculitis, hashimoto encephalitis (HE), neurosarcoidosis (NS), multi-system atrophy (MSA), migraine, chemotherapy-induced pain or dementia-related pain.

The present invention relates to dosing regimens and methods of using LY3154207, also described as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2 (1H)-yllethanone, and / or pharmaceutical compositions thereof, for treatment of dopaminergic central nervous system disorders. Dopaminergic CNS disorders of the present dosing regimen methods include Parkinson's Disease, Alzheimer's Disease, Lewy body dementia (LBD), Vascular Dementia, Schizophrenia, ADHD, Depression, Autism, chronic musculoskeletal pain, fibromyalgia, cognitive impairment disorders, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders.

The present invention provides compositions and methods for inhibiting the autoimmune component of neurodegenerative diseases and thereby providing a therapeutic effect to patients suffering from such diseases. The compositions and methods comprise immunosuppressive moieties, such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or that specifically bind to one or more glial cell markers. Therapeutically effective doses of the compounds for treating neurodegenerative diseases, including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and prion diseases, are disclosed.

The present invention provides compositions and methods for inhibiting the autoimmune component of neurodegenerative diseases and thereby providing a therapeutic effect to patients suffering from such diseases. The compositions and methods comprise immunosuppressive moieties, such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or proteins that specifically bind to one or more glial cell markers. Therapeutically effective doses of the compounds for treating neurodegenerative diseases, including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and prion diseases, are disclosed.

Compositions and methods for treating neuroinflammatory diseases and conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (AES), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), neuromyelitis optica (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), vascular dementia (VAD), anti-myelin oligodendrocyte glycoprotein antibody disease (MOGAD), transverse myelitis (TM), autoimmune encephalitis (AE), acute disseminated encephalomyelitis (ADEM), chronic meningitis (CM), central nervous system (CNS) vasculitis, Hashimoto's encephalitis (HE), neurosarcoidosis (NS), multiple system atrophy (MSA), migraine, chemotherapy-induced pain, or dementia-related pain, are provided herein.

This disclosure relates to methods of treating or preventing traumatic brain injury (TBI) or related conditions comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or alternative anionic polymer or a pharmaceutically acceptable salt thereof to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating chronic traumatic encephalopathy (CTE) comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or alternative anionic polymer, or a pharmaceutically acceptable salt thereof to subject in need thereof.